Pharma News

The precious chemistry of a plant used for 2,000 years in traditional Chinese medicine has been unlocked in a project that raises the prospect of rapid access to a wide array of therapeutic drugs.

Carried out by CEPAMS – a partnership between the Chinese Academy of Sciences and the John Innes Centre – the project has successfully delivered a high-quality reference genome of the mint-family member Scutellaria baicalensis Georgi.

Researchers have designed the first ‘living medicine’ to treat lung infections. The treatment targets Pseudomonas aeruginosa, a type of bacteria which is naturally resistant to many types of antibiotics and is a common source of infections in hospitals.

A new study identifies cells that are the most vulnerable within a brain structure involved in mood and movement.

Researchers at University of California San Diego School of Medicine have discovered a molecular pathway critical to the initiation of pancreatic tumors. The mechanism could also contribute to the disease’s high resistance to chemotherapy and its propensity for metastasis.

AI may help improve care for patients who show up at the hospital with acute chest pain, according to a study published in Radiology.

“To the best of our knowledge, our deep learning AI model is the first to utilize chest X-rays to identify individuals among acute chest pain patients who need immediate medical attention,” said the study’s lead author, Márton Kolossváry, MD, PhD, radiology research fellow at Massachusetts General Hospital (MGH) in Boston.

BDR Pharmaceutical launched the first generic APALUTAMIDE (Brand name APATIDE) in India to treat both Metastatic Castration Sensitive Prostrate Cancer as well as Non-Metastatic Castration resistant Prostrate Cancer. The product will be available across India and shall be of 60 mg strength and available in two packs - 60 tabs and 120 tabs. Apalutamide in combination with anti-androgen therapy will significantly improve chances for survival within Metastatic Castration Sensitive Prostrate Cancer patients.

Researchers in the United States and Japan have discovered a new mechanism that links age-related cartilage tissue stiffening with the repression of a key protein associated with longevity. These findings enhance the understanding of mechanisms that lead to the deterioration of joints that causes osteoarthritis, according to the authors of a new study, published January 10th in Nature Communications.

Doctors at Queen Mary University of London and Barts Hospital, and Cambridge University Hospital, have led research using a new type of CT scan to light up tiny nodules in a hormone gland and cure high blood pressure by their removal. The nodules are discovered in one-in-twenty people with high blood pressure.

Zydus Lifesciences Limited’s subsidiary Zydus Pharmaceuticals (USA) Inc. (Zydus) has received tentative approval from the United States Food and Drug Administration (USFDA) to market Levomilnacipran Extended-Release Capsules, 20 mg, 40 mg, 80 mg, and 120 mg (USRLD: Fetzima® Extended-Release Capsules).